Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-11-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事关于公司第七届董事会第二十七次（临时）会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting related to adjustments in a restricted stock incentive plan. It references compliance with company law, securities law, and stock exchange rules, and provides an independent judgment on the board's decisions. The content is focused on governance and board-level decisions rather than financial results or audit findings. The document length is short (597 characters), and it is not a full report but an opinion statement related to board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions and management.
2022-11-07 Chinese
关于第七届监事会第二十四次（临时）会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the approval of adjustments to the company's third restricted stock incentive plan. It details the meeting date, voting results, and references compliance with relevant laws and company regulations. The content focuses on corporate governance and internal management decisions related to stock incentive plans, without presenting financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or capital update. The document is an official announcement of a board/management decision, specifically about stock incentive adjustments, which fits best under Board/Management Information (MANG). The document length is short and does not contain financial data or detailed report content, so it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2022-11-07 Chinese
关于第七届董事会第二十七次（临时）会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at a board meeting regarding adjustments to a restricted stock incentive plan. It details the meeting date, attendance, voting results, and specific changes to the stock incentive plan. There is no financial report, earnings data, or regulatory filing of a financial nature. The content focuses on board decisions and management actions related to stock incentives. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management.
2022-11-07 Chinese
中国国际金融股份有限公司关于安徽安科生物工程（集团）股份有限公司第三期限制性股票激励计划调整事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the adjustment of the third restricted stock incentive plan of Anhui Anke Biological Engineering (Group) Co., Ltd. It contains detailed explanations about the stock incentive plan, approval procedures, grant details, and the independent financial advisor's opinions. The content focuses on the stock incentive plan adjustments and related financial advisory opinions rather than a general annual report or earnings release. It is not a simple announcement but a detailed advisory report. This fits the category of Capital/Financing Update (CAP) because it relates to stock incentive plans, which are a form of capital structure change and financing activity. The document length (6287 characters) and detailed content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2022-11-07 Chinese
关于公司双特异性抗体获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the approval of a clinical trial for a new drug (HK010 injection) by the National Medical Products Administration. It details the drug name, approval number, applicants, and the regulatory conclusion allowing clinical trials. The document also discusses the drug's development status and associated risks. There is no financial data, no mention of annual or quarterly reports, no shareholder voting results, no management changes, and no earnings information. The document is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-11-02 Chinese
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "安徽安科生物工程(集团)股份有限公司2022 年第三季度报告" which translates to "Anhui Anke Biological Engineering (Group) Co., Ltd. 2022 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow, and shareholder information for the third quarter of 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period ending September 30, 2022. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.